• Large Print

HR 4487

Title: Medical Innovation Act of 2017
Author: Rep. Peter Welch (DEM-VT)

Department of Health and Human Services (HHS) for each of its covered blockbuster drugs. A covered blockbuster drug is a drug that has at least $1 billion in net sales in a year and was developed, in whole or in part, through federal investments in medical research, including a drug for which a patent contains information that relates to, or is based upon, federally funded research.</p> <p>Each fiscal year, HHS must publish a list of manufacturers that make payments, each manufacturer's covered blockbuster drugs, and payment amounts.</p> <p>Payments are divided between the FDA and the NIH in proportion to the discretionary funding of those agencies, excluding FDA user fees. Payments are not disbursed if appropriations for the FDA or the NIH are lower than in the prior fiscal year.</p> ...

Introduced in House 11/29/2017
Introduced in House 11/29/2017
Referred to the House Committee on Energy and Commerce. 11/29/2017
Referred to the Subcommittee on Health. 12/01/2017

Bill Text
12/01/2017 - HR 4487 (Introduced+in+House)
11/29/2017 - HR 4487 (Introduced+in+House)

Add To Favorites In PHR

Author Details

    Rep. Peter Welch (D-VT)
    () - U.S. Representative

    Visit their Website

    Contact Tips

    Capital Address:
    2303 Rayburn House Office Building

    Washington, DC 20515-4500
    Phone: (202) 225-4115

    District Address:
    128 Lakeside Avenue, Suite 235

    Burlington, VT 05401
    Phone: (802) 652-2450


Driving Walking/Biking Public Transit  Get Directions